EGFR and ovarian carcinoma: The specific aim of this project was threefold: (1) to bioengineer suicide genes’ carrying vectors guided by synthetic nano-antibodies for EGFR and EGFRvIII; (2) to genetically engineer DNA constructs for the human, recombinant DNASE1, DNASE1L3, DNASE2, and DFFB controlled by the EGFR promoter; (3) to selectively eradicate ovarian cancer cells by intranuclear targeting of the expressed transgenic DNases.